Trial NCT04583995; EudraCT 2020-004123-16
Publication Heath P, Clin Infect Dis, 2022
Primary outcome on the report: Efficacy of the NVX-CoV2373 vaccine against the first occurrence of virologically confirmed symptomatic mild, moderate, or severe Covid-19 with onset at least 7 days after the second dose among participants who were seronegative at baseline, as determined by the results of testing for anti–nucleocapsid antibody.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.